<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00534872</url>
  </required_header>
  <id_info>
    <org_study_id>OXS109143</org_study_id>
    <nct_id>NCT00534872</nct_id>
  </id_info>
  <brief_title>A Clinical Study to Evaluate the Pharmacokinetic Profile of SB-649868 in Elderly and Female Population</brief_title>
  <official_title>A Single-centre, Open Label, Single-dose, Four Parallel Cohorts Study to Investigate the Pharmacokinetics, Safety and Tolerability of SB-649868 10mg in Healthy Female &quot;Non-childbearing Potential&quot;, Healthy Male and in Healthy Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the blood levels and the tolerability of SB-649868
      in Elderly and Female population
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The study was stoppend before recruitment start for preclinical safety finding in rats.
  </why_stopped>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">October 2007</completion_date>
  <primary_completion_date type="Anticipated">October 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood levels after a single dose of SB-649868 after 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 hours</measure>
    <time_frame>single dose of SB-649868 after 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36 and 48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Event, laboratory, vital signs and ECG abnormality occurred within 7-14 days from a single dose of SB-649868</measure>
    <time_frame>within 7-14 days from a single dose of SB-649868</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>SB649868</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB-649868</intervention_name>
    <description>10 mg</description>
    <arm_group_label>SB649868</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Healthy adult and elderly female and male

          -  Female must be of non-childbearing potential

          -  Body weight =50 kg

        EXCLUSION CRITERIA:

          -  Abuse of alcohol or drugs

          -  Positive for Hepatitis B surface antigen, Hepatitis C antibody or HIV

          -  Use of prescription or non-prescription drugs within 7 days prior to the first dose of
             study medication

          -  Smoking history of = 10 cigarettes a day in the last three months

          -  History of cardiovascular,psychiatric,autoimmune, respiratory or relevant
             gastrointestinal diseases

          -  Participation in clinical trial during the previous 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2007</study_first_submitted>
  <study_first_submitted_qc>September 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2007</study_first_posted>
  <last_update_submitted>April 15, 2015</last_update_submitted>
  <last_update_submitted_qc>April 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2015</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>GSK</organization>
  </responsible_party>
  <keyword>4 Parallel cohorts</keyword>
  <keyword>Healthy Female</keyword>
  <keyword>Healthy Elderly</keyword>
  <keyword>Pharmacokinetic</keyword>
  <keyword>Safety and Tolerability</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

